Based on these findings, we suggest that close monitoring of lesion progression and more aggressive intervention such as surgery and novel therapeutics should be applied to IPMN with concomitant mutations of KRAS and RNF43. The gene discussed is RNF43; the disease is pancreatic intraductal papillary-mucinous neoplasm.